A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the novel oral agent VT-1161 is safe and
effective in treating patients with acute vulvovaginal candidiasis (also referred to as yeast
infection). VT-1161 has been designed to inhibit CYP51, an enzyme essential for fungal
growth. Inhibition of CYP51 results in the accumulation of chemicals know to be toxic to the
fungus. CYP51 is the molecular target of the class of drugs referred to as 'azole
antifungals'. All currently approved azole drugs have poor selectivity for CYP51 and this
results in many of the side effects associated with the azole antifungals. The safety profile
of the class similarly limits use in chronic treatment of non-life-threatening fungal
infections. VT-1161 has been design to be safer and more active against the fungal species
typically responsible for vaginal yeast infections (i.e. vulvovaginal candidiasis).